Pierre Legault is the former Chief Executive Officer of NephroGenex and has been a member of the Company’s Board of Directors since November 2012. Mr. Legault formerly served as CEO of Prosidion Ltd., a mid-size U.K. biotechnology firm.
Mr. Legault has also served as Executive VP, Chief Financial Officer and Treasurer with OSI Pharmaceuticals, Senior Executive VP and Chief Administrative Officer of Rite Aid Corporation, and President of the Eckerd Group, with overall manager responsibilities for the Brooks Eckerd operations in the U.S. Mr. Legault also held several senior positions with Sanofi-Aventis and predecessor companies.
Mr. Legault previously served on the boards of Forest Laboratories, Inc. and Cyclacel Pharmaceutical Inc. He studied at McGill University, University of Montreal (HEC) and the Harvard Business School, and holds a Six Sigma Green Belt, a BAA, MBA, CA and CPA diploma.
James Mitchum has served as Chair of the Audit Committee on the Board of Directors since February 2014. Mr. Mitchum is the CEO of Heart to Heart International, a crisis and medical relief organization based in Kansas City. From 2009 to July 2012, Mr. Mitchum served as President of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011.
Previously, Mr. Mitchum served as President and Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City, Missouri. He also served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan, as well as director on numerous private company and organization boards.
Mr. Mitchum earned an MBA in Business from the University of Tennessee in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.
Robert R. Seltzer
Robert R. Seltzer has been on the Board of Directors since October 2013. Mr. Seltzer is a Managing Partner at Amzak Health, an investment firm focused on venture capital and growth equity opportunities in healthcare. Prior to joining Amzak Health in 2015, Mr. Seltzer was a Partner at Care Capital, a life sciences venture capital firm, where he spent over ten years investing in the healthcare sector. In that capacity, he served on the Board of Directors of a number of biopharmaceutical and drug development companies. Prior to his investing career, Mr. Seltzer was a management consultant at the Boston Consulting Group, and was previously Co-Founder and President of Trenza Corp.
Mr. Seltzer received his MBA from The Wharton School, a Masters in Biotechnology from the University of Pennsylvania, and a BS in Molecular Biophysics and Biochemistry from Yale University.